Bevacizumab and Carboplatin for Patients With Platin Resistant Epithelial Ovarian Cancer. A Phase II Study.

Trial Profile

Bevacizumab and Carboplatin for Patients With Platin Resistant Epithelial Ovarian Cancer. A Phase II Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 23 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 23 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top